Management of complications of bacillus Calmette-Guerin immunotherapy in the treatment of bladder cancer

Annals of Pharmacotherapy

Volumn 34, Issue 4, 2000, Pages 529-532

  Huang, Tammy C ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

Bacillus Calmette Guerin; BCG; Bladder cancer

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; HUMAN; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0034029227     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19145     Document Type: Article

References (12)

1. Jansson OT, Morcos E, Brundin L, Lundberg JO, Adolfsson J, Soderhall M. et al. The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer 1998;78:588-92.
2. Vegt PDJ, Debruyne FMJ, van der Meijden APM. Bacillus Calmette-Guérin in superficial bladder cancer: consensus and controversies. Eur Urol 1995;27:89-95.
3. Steg A, Lelev C, Boccon-Gibod B, Sicard D. Systemic bacillus Calmette-Guérin infection, "BCGitis," in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 1989;16: 161-4.
4. Sosnowski JT. Complications of bacillus Calmette-Guérin (BCG) immunotherapy in superficial bladder cancer. Compr Ther 1994;20:695-701.
5. Groves MJ. Pharmaceutical characterization of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine used for the treatment of superficial bladder cancer. J Pharm Sci 1993;82:555-62.
6. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
7. Paterson DL, Patel A. Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. Aust N Z J Surgi 1998;68:340-4.
8. Steg A, Adjiman S, Debre B. BCG therapy in superficial bladder tumours - complications and precautions. Eur Urol 1992;21(suppl 2):35-40.
9. Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Holtl W, de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 1997;157:1246-9.
10. Grange JM. Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998;1:84-8.
11. Proctor DD, Chopra S, Rubenstein SC, Jokela JA, Uhl L. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guérin instillation for bladder carcinoma. Am J Gastroenterol 1993;88:1112-5.
12. Kirsten D, Rieger U, Schröder KH, Bohle A, Magnussen H. Pulmonary tuberculosis due to bacille Calmette-Guérin. Clin Investig 1993;71:787-90.